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ABSTRACT
An analysis of NMDP data shows that allele-level matching for HLA A, B, C, and DRB1 is preferred in the se-
lection of adult unrelated donors. If mismatching is unavoidable, mismatches at HLA B or C may be better tol-
erated than those at A orDRB1.Whethermismatches are at the allele level (ie, within an antigen group) or at the
antigen level makes no difference in outcome, except at HLA C where allele mismatches are better tolerated.
Matching forHLADQandDP should be prioritized belowmatching at the 4major loci. These findings are com-
pared and contrasted with previous publications.
The impact of HLAmatching onmajor outcomes in umbilical cord blood (UCB) transplantation continues to be
refined. Total nucleated cell dose was previously thought to be sole determinant of outcome with partially HLA
matchedUCB transplantation, butHLAmatching, particularly at low total nucleated cell dose, appears to play an
important role. Relatively small sample sizes limit the consistency of findings from cord blood studies, but the
consensus supports consideration of both total nucleated cell dose andHLAmatching in the selection of optimal
UCB units. As search considerations for both adult donors and umbilical cord blood units have become more
complex, the National Marrow Donor Program has developed software, services and relationships to ease the
burden on transplant teams.
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Hematopoietic cell transplantation (HCT) from
adult unrelated donors and unrelated umbilical cord
blood (UCB) units can cure patients with malignant
and nonmalignant hematologic diseases who lack
a suitable family member donor. The National
Marrow Donor Program (NMDP) facilitates more
than 300 HCT each month. Although most of these
are adult donor transplants, UCB HCT comprises
nearly 20% of the total and continues to increase.
The NMDP registry lists more than 6.7 million adult
donors and 68,000 UCB units. An additional 5 million
adult donors and 200,000 UCB units are available for
search through international collaborations. Selection
of the best available adult donor or UCB unit is neces-
sary to maximize the likelihood of successful HCT.
The principles of optimal donor/UCB unit selection
are continuing to evolve, and the tools for simplifying
the process continue to improve.112SELECTING ADULT UNRELATED DONORS
Currently in the NMDP experience, up to 70% of
patients undergo unrelated donor transplantation
using an HLA-A, B, C, and DRB1 allele-matched
unrelated donor, and some have multiple 8/8 allele
matched donors identified. For these patients, the
question is how to choose a donor among several
HLA-matched possibilities based on criteria such as
donor age [1]. For the approximately 30% for whom
an 8/8 allele-matched donor cannot be identified,
how should the best mismatched donor be selected?
Recent results from a NMDP analysis are summarized
followed by a discussion of relevant previous studies.
HLA-A, B, C, and DRB1
Increasing genetic disparity, particularly for hu-
man leukocyte antigen (HLA) molecules, is associated
with greater risks of acute graft-versus-host disease
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lower survival in HCT. The NMDP recently analyzed
3857 transplant procedures and reported several key
findings [2]: (1) high-resolution DNA matching for
HLA-A, B, C, and DRB1 (8 of 8 match) was confirmed
as the minimum level of matching associated with the
highest survival. A single mismatch detected by low- or
high-resolution DNA testing at HLA-A, B, C, or
DRB1 (7 of 8 match) was associated with higher
mortality (relative risk 1.25, 95% confidence interval
[CI] 1.13-1.38, P \ .0001) and 1-year survival of
43% compared to 52% for 8 of 8 matched pairs.
Mismatching at 2 or more loci compounded the mor-
tality risk. (2) An allele mismatch was associated with
the same statistical decrement in survival as an antigen
mismatch, except for HLA-C where the lower survival
was primarily associated with antigen mismatches. (3)
Single mismatches at HLA-A or HLA-DRB1 appear
more poorly tolerated than mismatches at HLA-B or
HLA-C (relative risk [RR] 1.18, 95% CI 1.10-1.38,
P5 .04) (Table 1). (4) Single mismatches were also as-
sociated with treatment-related mortality and
aGVHD. There was no statistically significant differ-
ence between 7 of 8 (either allele or antigen) and 8 of
8 matched pairs for relapse, chronic GVHD
(cGVHD), and engraftment.
Transplant procedures were performed between
1988-2003 using myeloablative conditioning and
primarily bone marrow as a stem cell source. Diseases
included acute myeloid leukemia, acute lymphoblastic
leukemia, chronic myeloid leukemia, and myelodys-
plastic syndrome. Pairs mismatched at specific loci
were compared with 8 of 8 HLA matched pairs, in con-
trast to previous studies that relied on multivariable
models to adjust for multiple mismatches [3] or
grouped different mismatches together before
performing subgroup comparisons [4]. Because of
multiple testing, a P-value\.01 was considered statis-
tically significant. Although this approach more pre-
cisely estimates the association between specific
mismatches and outcomes, limited patient numbers
in certain subsets may severely limit the power of the
analysis for those subgroups.HLA-DQ
In the NMDP analysis discussed above, a single
HLA-DQ mismatch was not associated with any
adverse outcomes. If a pair is already mismatched at an-
other locus, adding an additional HLA-DQ mismatch
was associated with a mortality risk of 1.15, 95% CI
0.95-1.39, P 5 .14. Among 6 of 8 matched pairs, the
mortality risk associated with an additional HLA-DQ
mismatch was 1.20, 95% CI 0.98-1.46, P 5 .08. Thus,
if a pair is otherwise matched at HLA-A, B, C, and
DRB1, the NMDP analysis suggests additional testing
for HLA-DQ is not necessary because single HLA-
DQ mismatches were not associated with increased
mortality. However, if 1 or more other mismatches
are present, HLA-DQ matched donors should be
favored given the same degree of matching at other loci.
HLA-DP
HLA-DP locus mismatches were common in
otherwise well-matched pairs. There was no association
of HLA-DP mismatching with survival or disease-free
survival (DFS) in the multivariate analysis. However,
increased aGVHD (RR 1.43, 95% CI 1.16-1.76, P 5
.0009) and a trend toward a lower relapse rate (RR
0.74, 95% CI 0.57-0.96, P 5 .02) was seen with HLA-
DP mismatching, consistent with prior reports [5-8].
Donor Age and Other Characteristics
Multivariate models were constructed to identify
factors predictive of patient survival. HLA matching
was highly statistically significant, as were patient
age, race, disease stage, and CMV status. Donor
factors, such as age, parity, CMV status, and gender
were not significantly associated with patient survival,
suggesting that HLA matching should be the primary
determinant in donor selection.
Current Results in the Context of Past Findings
This section reviews the survival results presented
above in the context of other published literature from
the NMDP and 2 other groups, the Fred HutchinsonTable 1. Single Allele or Antigen Mismatches at HLA-A, B, C, and DRB1 in Adult Unrelated Donor Transplantation
Survival Treatment-Related Mortality Acute Graft-versus-Host Disease
n* RR 95% CI P-Value RR 95% CI P-Value RR 95% CI P-Value
8 of 8 matched 1840 1.00 1.00 1.00
A mismatch 274 1.36 1.17-1.58 \.0001 1.47 1.22-1.77 \.001 1.57 1.27-1.94 \.0001
B mismatch 116 1.16 0.92-1.47 .20 1.32 1.02-1.73 .03 1.63 1.22-2.17 .001
C mismatch 478 1.19 1.05-1.35 .006 1.32 1.14-1.52 .0002 1.43 1.20-1.70 \.0001
DR mismatch 117 1.48 1.19-1.85 .0005 1.56 1.21-2.01 .0007 1.27 0.91-1.77 .16
HLA indicates human leukocyte antigen; RR, relative risk; CI, confidence interval.
*n for survival model. Other models may had fewer evaluable patients.
114 S. J. Lee et al.Cancer Research Center (FHCRC) and the Japan
Marrow Donor Program (JMDP).
In 1995, Petersdorf and colleagues [9] at the
FHCRC in Seattle analyzed 364 patients and reported
that HLA-DRB1 allele mismatching was associated
with higher rates of aGVHD and mortality. Subse-
quently, in 1996, they reported that HLA-DQB1
mismatching was also associated with grade III-IV
aGVHD in 449 patients, although survival was not
evaluated [10]. The next FHCRC publication in
1998 analyzed 300 CML patients and found that 2 or
more class I and combined class I and II allele
mismatches were associated with graft failure and
mortality [11]. In 2001, they extended this analysis to
471 CML patients and reported that single antigen
but not allele class I mismatches were associated with
graft failure. Survival at 5 years was not statistically dif-
ferent between single class I allele mismatched pairs,
single class I antigen mismatched pairs, and matched
patients [5]. Petersdorf et al [12], in 2004, analyzed
948 patients using both HLA-mismatched subset
comparisons and multivariate analysis and reported
that a single allele or antigen mismatch was associated
with higher mortality in early-phase disease, defined as
CML in chronic phase within 2 years of diagnosis, but
not in patients with more advanced disease. In partic-
ular, a single disparity at HLA-C (n 5 24) was associ-
ated with lower survival as was an HLA-DQ mismatch
in combination with other mismatches. They also
found that single allele and single antigen mismatched
pairs had similar mortality.
The current NMDP study is consistent with the
Seattle results in that allele and antigen mismatches
are associated with similar adverse outcomes in early-
phase disease. However, the NMDP studies have
also documented lower survival for single mismatches
in patients with advanced disease phases, while con-
versely, failing to find a statistically significant adverse
effect of HLA-DQ mismatching in combination with
other mismatches. The larger NMDP sample size
and consequent ability to emphasize comparison of
single locus mismatched pairs to fully matched pairs
may explain some of these differences.
A second set of studies comes from the JMDP.
These mostly focus on pairs already serologically
matched for HLA-A, B, and DR. In 1998, JMDP
reported that HLA-A mismatches were associated
with higher grade III-IV aGVHD and mortality.
HLA-C mismatches were associated with higher
aGVHD and lower relapse, but no difference in sur-
vival, and class II mismatches were not associated
with either aGVHD or survival. Multivariate model-
ing, controlling for any additional mismatches present,
was used to analyze 440 pairs [13]. In 2002, JMDP
updated their analysis, including 1298 pairs. In this re-
port, they performed both multivariate analyses and
subset analysis comparing mismatched to fullymatched pairs. Because of limited numbers, they
analyzed 3 subsets: HLA-A and/or HLA-B, HLA-C,
and DRB1 and/or DQB1. All subgroups were associ-
ated with grade III-IV aGVHD but only HLA-A
and/or HLA-B mismatches were associated with
higher mortality and cGVHD [4]. More recently, the
JMDP published a study identifying 15 specific allele
combination mismatches (at least 1 in each locus)
associated with severe grade III-IV aGVHD. Further
analysis showed 6 specific amino acid substitution
positions in HLA class I were associated with severe
aGVHD [14].
The current NMDP study is consistent with
JMDP reports in that high-resolution mismatching
at HLA-A is associated with increased mortality, but
high-resolution mismatching at HLA-C is not. Unlike
the JMDP, we also found increased mortality among
104 transplants with a single DRB1 high-resolution
mismatch6 a DQB1 mismatch, whereas JMDP found
similar nonrelapse mortality among 116 patients with
DRB1 and/or DQB1 mismatches compared to fully
matched pairs. It is possible that relatively small
numbers, rather than the biology of HLA-DR in the
2 ethnic groups, accounts for the different conclusions.
The NMDP has published 2 earlier studies
examining HLA matching in adult unrelated donor
HCT. In 2001, the NMDP analyzed 831 patients
with CML in a chronic or accelerated phase, and re-
ported that HLA-DRB1 allele mismatching was asso-
ciated with lower relapse-free (RFS) and overall
survival (OS) [15]. In 2004, an NMDP study led by
Flomenberg analyzed 1874 pairs and reported that
low-resolution mismatches at HLA-A, B, C, and
DRB1 were associated with similar decrements in
survival. In contrast, mismatches detected only with
high-resolution typing were not statistically associated
with lower survival at P \ .01. HLA-A mismatches
were associated with higher grade III-IV aGVHD
and cGVHD. Mismatches at HLA-DQ and HLA-
DP were not associated with survival differences [3].
Although patients in the 2004 NMDP study com-
prised 34% of the pairs in the current study, several
findings differed. First, in the current 2007 study,
both allele and antigen mismatches were roughly
equivalent (except for HLA-C), whereas the 2004
study found that antigen mismatches fared more
poorly than allele mismatched pairs. Second, in the
2007 study, HLA-A, HLA-C, and HLA-DR mis-
matches were associated with higher mortality than
HLA-B, whereas the 2004 study concluded that mis-
matches at these 4 loci were approximately equivalent.
These discrepancies may be explained by differences in
study population and method of analysis. The 2007
study was limited to patients with AML, ALL, CML,
and MDS, and compared outcomes between fully
matched patients and defined subsets of patients with
specific mismatches, providing independent risk
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The 2004 study included more heterogeneous dis-
eases, including 9% nonmalignant diagnoses, and uti-
lized multivariate modeling to adjust for the presence
of additional mismatched loci.
The estimated effect of donor age on survival is
controversial. The current 2007 NMDP study did
not find a statistically significant association between
donor age and patient survival. Using donor age\31
years as the baseline, donor age 31-45 years was
associated with a RR 1.05, 95% CI 0.95-1.16, P 5
.38 and .45 years, with an RR of 1.06, (95% CI
0.93-1.20, P 5 .42). In contrast, a previous 2001
NMDP study by Kollman found that each decade of
donor age was associated with an RR of 1.10 (95%
CI 1.06-1.14, P\ .0001) [16]. The 2001 NMDP study
included twice as many patients (N5 6978), used sero-
logic typing for class I loci, had a median follow-up of
only 2 years, and included 17% with different diseases
than our population.
CONCLUSION
Increasingly large numbers of unrelated donor
pairs allow more refined studies of the association
between HLA matching and the success of unrelated
donor transplantation. However, the constant evolu-
tion of graft sources, conditioning regimens, GVHD
prophylaxis regimens, and supportive care guarantees
that solid data to guide donor selection will always
lag behind current practice to some extent. Neverthe-
less, donor decisions need to be made today, and these
data are the best available evidence to help select the
optimal donors. Based on the most recent NMDP
study, donor selection should be based on high-
resolution matching at HLA-A, B, C, and DRB1 so
as to maximize the chance for a successful transplant.
If a fully allele-matched donor at HLA-A, B, C, and
DRB1 is not available and multiple mismatched
donors are fully typed, then single mismatches at
HLA-B or HLA-C are better tolerated than single
HLA-A or DRB1 mismatches in our study. We could
not document a difference between the adverse effects
of allele and antigen mismatches, except perhaps for
HLA-C, where only antigen mismatches were associ-
ated with worse outcomes. Although HLA-DQ and
HLA-DP matching and younger donor age were not
statistically significantly associated with mortality in
this study, it is reasonable to prioritize HLA-DQ and
HLA-DP matched and younger donors if other HLA
considerations are equal and complete high-resolution
typing is known.
SELECTING UMBILICAL CORD BLOOD UNITS
Since the initial report of the successful use of
partially HLA-mismatched unrelated donor UCB as
a source of hematopoietic stem cells by Kurtzberget al [17], in 1996, several studies have shown that
the results of HCT using HLA-matched or partially
mismatched unrelated donor UCB are comparable to
those using unrelated donor bone marrow [18-22].
UCB is now accepted as an alternative source of hema-
topoietic stem cells for unrelated donor transplanta-
tion, with over 8000 UCB transplants performed
worldwide [23].
It is important to note that the majority of UCB
HCT reported in the literature has utilized matching
at the antigen level for HLA-A and HLA-B loci typed
either by serology or low- to intermediate-resolution
DNA-based methods, and at the allele level for
HLA-DRB1 loci. The current standard for UCB
unit selection is thus based on HLA matching at low
to intermediate resolution for HLA-A and B and
allele-level matching for DRB1 with donor-recipient
match status categorized as a 6 of 6, 5 of 6, or 4 of 6
match.
Similar to the results of studies in adult unrelated
donor HCT, it is likely that allele-level disparity be-
tween donor and recipient may also impact transplant
outcomes, although the paucity of data in this regard
is a limitation in determining the current role of al-
lele-level HLA matching in UCB HCT. Retrospective
studies of UCB HCT utilizing allele-level matching
data have shown that when the original HLA match is
compared to the final one, the HLA match status is de-
moted in almost a third of donor/recipient pairs [24].
As an example, a study by Kogler et al [25] of 122
donor-recipient pairs showed that over half (9 of 16)
of the patients initially thought to be 6 of 6 matched ac-
tually had lower levels of match at the allele level.
Impact of HLA Matching on Engraftment after
UCB HCT
UCB HCT differs from either unrelated bone
marrow or peripheral blood stem cell transplantation
in that there is a significant delay in the time to engraft-
ment and the overall probability of engraftment is
lower with UCB [18,19,21,22,26,27]. Studies of
UCB HCT have shown that the total nucleated cell
dose is a critical factor that is strongly correlated
with hematopoietic engraftment [28-30]. Other
studies suggest that the CD341 cell dose [31] or the
graft progenitor cell content as measured by colony-
forming cells [32] may be more important determi-
nants of hematopoietic recovery post-UCB HCT,
but the nucleated cell dose is more widely accepted
as the criterion by which UCB units are selected
because quantification of CD341 cells or colony-
forming cells is difficult to standardize from bank to
bank.
In addition to graft cell dose, analyses of outcomes
following UCB HCT also suggest an impact of donor-
recipient HLA matching on engraftment. In the
largest analysis done to date on 562 UCB HCT
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is a progressive delay in myeloid engraftment by day 42
with increasing HLA mismatching. In their analysis
100% of patients receiving 6 of 6 matched transplants
engrafted (n5 40) compared to 78% of 211 recipients
of 5 of 6 matched UCB HCT, 82% of 257 recipients of
4 of 6 matched UCB HCT, and 69% of 39 patients re-
ceiving grafts mismatched at 3 or more loci (P 5 .01).
They could not detect a significant difference in mye-
loid engraftment between those who received grafts
mismatched at 1 or 2 antigens. In the COBLT study,
multivariate analysis showed that a higher original
HLA match (5 or 6 of 6) correlated with neutrophil
recovery (P 5 .04) [27].
The interaction of cell dose with HLA was ana-
lyzed in a recent study by Eapen et al [19], comparing
outcomes of 503 UCB HCT and 282 adult unrelated
donor HCT in children with acute leukemia. A cutoff
for total nucleated cell dose for 1 antigen mismatched
transplants was defined as 3  10e7/kg. They found
that the probability of neutrophil recovery by day 42
and platelet recovery by 6 months was similar after
marrow or 6 of 6 matched UCB HCT, but lower for
mismatched UCB HCT at both low and high cell
doses compared to UBMT. Higher cell doses resulted
in a higher probability of both neutrophil and platelet
recovery in 1 antigen-mismatched UCB HCT, but had
no effect in 2-antigen mismatched transplants,
suggesting that cell dose may not be able to overcome
the adverse impact of mismatching in the setting of 4 of
6 matched UCB HCT.
In an analysis of 550 UCB HCT by the European
Blood and Marrow Transplant Group, the 60 day
cumulative incidence of neutrophil engraftment was
83% for those with no HLA disparities compared to
53.2% for those with $3 disparities (P 5 .001) with
a log-linear relationship between increasing HLA dis-
parity and risk of graft failure. Only 263 of 550 patients
achieved an untransfused platelet count of 20,000/mL
by day 180 with an absence of both HLA-A, B, and
DRB1 disparities being correlated with a higher 180-
day cumulative incidence of platelet recovery (P 5
.006). No statistically significant interaction between
the cell dose and HLA disparities for either neutrophil
or platelet recovery could be demonstrated [34].
Impact of HLA Matching on GVHD
Several analyses of UCB HCT have assessed the
impact of HLA matching on GVHD incidence. Anal-
ysis of the New York Blood Center’s experience shows
a trend, suggesting an impact of matching on risk of
severe grade III-IV GVHD with recipients of matched
UCB showing a lower GVHD risk compared to recip-
ients of mismatched UCB (P5 .06) [29]. The analysis
of Eurocord data shows that the risk of grade III-IV
GVHD is higher in recipients of UCB where class Iand II disparities coexist between donor and recipient
[34]. In the COBLT study, multivariate analysis
showed that HLA matching impacted grade II-IV
aGVHD risk, with a significantly higher risk of
aGVHD in recipients of 4 of 6 matched UCB com-
pared to 5 of 6 and 6 of 6 matched UCB (P 5 .03)
[27]. The outcome comparison study of unrelated
BM versus UCB by Eapen et al [19] failed to show
a correlation between HLA match and aGVHD or
cGVHD risk among recipients of UCB transplants.
Role of HLA Compatibility on Survival after UCB
HCT
Analyses by Rubinstein et al [29] and Wagner et al
[31], have identified a detrimental effect of HLA-A, B,
and DRB1 mismatching on survival. In a multivariable
Cox model, Rubinstein et al [29] found a higher risk of
adverse events (defined as death, autologous reconsti-
tution or second transplant) in 217 UCB HCT with
1 mismatch (RR 5 2.0), and 300 UCB HCT with 2
or more mismatches (RR 5 2.5) compared with 40
matched UCB transplants. Although the power of
the study was limited, there was no significant effect
of the number of mismatched loci, type of mismatched
locus, and level of typing resolution utilized to define
the mismatch at DRB1. Wagner et al [31] found an
increased risk of death (RR5 2.4) among 44 recipients
of UCB HCT mismatched for 2-3 loci, compared to
58 recipients mismatched for 0-1 locus (P 5 .01).
Eapen et al [19] evaluated treatment failure as the in-
verse of leukemia-free survival and showed a favorable
outcome for matched UCB HCT compared to 1 to 2
antigen mismatched UCB HCT or matched or
allele-mismatched UBMT (P5 .041). It is to be noted
there were only 35 patients in the matched UCB
cohort, but suggests that HLA matching may be of
strong import in outcome after UCB HCT. In con-
trast to the above studies, a study of 550 UCB HCT
by Eurocord [34] failed to find an effect of HLA dis-
parity on 3-year survival. Although the reasons for
the disparate results are not obvious, it is possible
that a cell dose interaction may be contributory
because it did not enter the multivariable model in
the Eurocord study. In this analysis, HLA disparity
did impact survival for patients with nonmalignant dis-
eases [23]. Table 2 summarizes the findings of the larg-
est studies to date that have evaluated the role of HLA
match on survival following UCB HCT.
In the COBLT study, multivariate analysis using
retrospective high-resolution typing data showed
that there was a significant increase in the incidence
of grades II-IV and III-IV aGVHD (P 5 .02) and
a significant decrease in survival probability when
a 2-4 of 6 matched UCB HCT was compared to 5-6
of 6 matched transplants (P 5 .04) [27]. Although
a few other studies have shown a positive effect of
high-resolution HLA matching on survival after
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HLA-A, B, DRB1 match
status* Rubinstein et al [29] Wagner et al [31] Gluckman et al [34] Eapen et al [19]‡ Kurtzberg et al [27]
5/6 Decrease Decrease No effect† Decrease Not evaluated
# 4/6 Decrease Decrease No effect† Decrease Decrease
*Mismatch count based on antigen-level match at HLA-A, B, and allele level at HLA-DRB1.
†Cell dose was not considered in the multivariate analysis.
‡Leukemia-free survival.UCB HCT, these data should be interpreted with cau-
tion because of the small numbers of patients analyzed.
When interpreting all the analyses described
above, the following limitations need to be kept in
mind. First, only a small proportion of patients have
received fully matched UCB transplants. Second, the
majority of transplants performed to date have been
1 or 2 antigen mismatched, and larger patient numbers
will be required to fully determine the differences
between these 2 cohorts. Third, although there are
suggestions of an interaction between cell dose and
HLA matching, small sample sizes have limited the
investigation of this interaction. Patient age and cell
dose may also be confounding variables.
Additional factors that may influence how a trans-
plant physician chooses UCB units include the UCB
bank, whether the unit was red cell depleted prior to
cryopreservation, availability of attached segments
for confirmatory typing and infectious disease marker
characteristics of the unit. No data currently exist to
assist us in evaluating the role of these in engraftment
or survival after UCB transplantation.
CONCLUSION
UCB graft cell dose is a critical determinant of
hematopoietic recovery and survival after UCB
HCT, but there is increasing evidence that HLA
match is also a key factor in UCB HCT outcome.
Current data suggest that HLA match is critically im-
portant in the setting of a low cell dose. The complete
elucidation of the impact of graft dose and match on
UCB HCT outcome will require the analysis of larger
cohorts of patients. The impact of a 1 versus 2 antigen
mismatch, the ‘‘trade-off’’ between HLA-match and
cell dose in unit selection, the importance of allele-
level matching at HLA-A and B, the match vector,
and whether HLA-C or DQB1 should be considered
in the selection of UCB units for transplantation can-
not be fully discerned at the current time. Currently,
the NMDP recommends typing all loci (A, B, C,
DRB1, and DQB) at the allele level. Matching should
follow the current standard of intermediate level for
HLA A and B, and allele level for HLA DRB1. All
recommendations are based on selection of a unit
with an appropriate cell dose. Currently available
data would consider this to be a unit that has .2.5-3 10e7 total precryopreserved nucleated cells per kg
recipient body weight.
Tools for Locating the Optimal Adult Donor or
UCB Unit
The process for identifying and ultimately select-
ing an unrelated donor or UCB is the responsibility
of the transplant center. NMDP has published recom-
mendations about how to search for adult bone mar-
row donors, and a similar set of recommendations
concerning UCB units is under consideration [1,35].
NMDP provides software to transplant centers
(TRANS Link) that allows real-time searching of
the complete NMDP inventory of adult donors and
UCB units. TRANS Link produces a donor/UCB
list that is sorted with the best of potential donors/
UCB at the top. Within HLA match grades, UCB
are prioritized according to total nucleated cell
(TNC) content, whereas adult donors are prioritized
by HLA matching likelihood alone. An NMDP
innovation named HapLogicsm predicts the likelihood
of allele-level matching based on calculated HLA
haplotype frequencies within major racial and ethnic
populations [36]. Currently, HapLogic predicts high-
resolution matching at HLA A, B, and DRB1, but
a future release in active development will also
consider HLA C and DQ. TRANS Link allows the
user to further customize the search results by priori-
tizing specific HLA loci or donor/UCB characteristics
(age, sex, CMV status, etc.). Currently, using TRANS
Link requires that a software program is installed on
the user’s computer that accesses the NMDP databases
through the Internet. A future release of NMDP
matching software will allow access through a standard
WWW browser interface (eg, Internet Explorer,
Firefox).
Another NMDP software product is the Multi-
Cord Tool. The Multi-Cord Tool evaluates HLA
matching between the proposed recipient and the
UCB units as well as the matching between UCB units.
The tool was developed to simplify the UCB selection
process for double cord transplantation. It can operate
on the UCB units from the NMDP search, from
a Bone Marrow Donors Worldwide (BMDW) search,
or those hand-entered by the user. The Multi-Cord
Tool is provided at no charge, and access is granted
through the NMDP Center for Cord Blood.
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non-U.S. donors and several thousand UCB units
from its participating international centers/banks in
the upfront TRANS Link search, additional adult
donors and UCB units are accessible only through
cooperative registry/cord blood bank agreements.
BMDW provides its online search as a convenient
way to target registries and banks for further inquiries
[37]. The NMDP automatically searches BMDW with
every new search submission. Several registries, in-
cluding NMDP, also automatically exchange donor
and UCB search information using the messaging pro-
tocol, EMDIS (European Marrow Donor Information
System, www.zkrd.de/emdis.html). For registries that
have not implemented EMDIS, the searching process
is largely manual, involving facsimile transmissions
and e-mail messages.
Up-to-date HLA information is available through
several Web resources. The NMDP maintains 2 useful
Web sites: www.nmdpresearch.org and bioinforma-
tics.nmdp.org. The latter provides links to the
IMGT/HLA database, which includes sequence infor-
mation on all recognized human HLA alleles.
The NMDP also provides human resources to as-
sist in the unrelated adult donor and UCB units search
process. NMDP HLA consultations are available for
any active patient search to provide estimates of the
likely best available matches and strategies for con-
ducting complicated or alternative searches. An HLA
consultation service is also available through
BMDW. In addition, the NMDP has begun to offer
Centralized Search Service. With Centralized Search
Service the transplant center provides a list of adult
donor or UCB unit criteria from which the NMDP
will manage the entire search process. The transplant
center receives a listing of the best available adult
donors or UCB units from which a final selection
can be made. Finally, the NMDP Office of Patient
Advocacy (OPA) provides a number of services for
patients including review of search results and explana-
tions of the search process. The OPA maintains a toll-
free telephone access (1-888-999-6743).
SUMMARY
Information to guide the selection of adult unre-
lated donors and UCB units continues to improve.
For adult donors, allele-level matching at HLA A, B,
C, and DRB1 is first priority, followed by matching
at DQ and DP. If a mismatch among the priority
loci cannot be avoided, mismatches at HLA B or C
may be better tolerated than those at HLA A or
DRB1. Allele mismatches appear as detrimental to sur-
vival as antigen mismatches, with the exception of
HLA-C. In UCB transplantation, where cell dose
was once thought to be the sole determinant of out-
come, HLA has emerged as an additional importantfactor for unit selection. The data support matching
for intermediate level HLA A, B, and allele level for
DRB1 with a preference for 6 of 6 over 5 of 6 over 4
of 6. Higher TNC doses appear to overcome at least
partially the negative impact of HLA mismatching.
The role of additional HLA loci in UCB HCT
remains to be defined.
When searching for an optimal graft, consolidated
listings, sophisticated computer algorithms, and expert
human assistance can reduce the burden on transplant
center staff. NMDP, BMDW, and international regis-
tries have supplied a number of tools and services to
assist transplant centers in finding the best possible
grafts for their patients.
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